·
·
Tech & Science
A new clinical trial in Russia tests a rapid, low-cost system for analyzing gut microbes to combat obesity and digestive disorders.
A team of scientists in Russia has launched clinical trials for a novel system designed to analyze intestinal microbiota, targeting obesity and gastrointestinal issues. The system, developed by experts at the Scientific and Technological Institute for Metabolic Health at the First Moscow State Medical University, uses multiplex polymerase chain reaction technology to deliver same-day results.
According to Vladimir Ivashkin, an academic and researcher at the Russian Academy of Sciences, the new system evaluates the quantitative composition of gut microbes, including pathogenic bacteria and Candida fungi, at a low cost. He noted that this technology could be applied to treat gastrointestinal diseases, immune disorders, anxiety disorders, obesity, and other conditions linked to the gut-brain and gut-immune axes.
The approach helps doctors design treatments tailored to each patient's unique gut microbiome composition. By providing rapid analysis, it enables more precise prescriptions for individuals suffering from obesity and digestive ailments.
Researcher Roman Maslennikov explained that quantifying gut bacteria will allow for more effective drug prescriptions and personalized therapies based on probiotics. He emphasized that research in this area is ongoing.
The clinical trials mark a step toward affordable, rapid diagnostics that could shift treatment strategies from generalized approaches to microbiome-specific interventions.
